← Trials/Trial dossier/NCT00065767

CompletedPhase 2 / PHASE3

Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

Lead sponsor

University of Wisconsin, Madison

Asset

raloxifene

Listed sites

Recruiting sites

Enrollment

Study population

Alzheimer’s disease

Key I/E criteria

•Age 55-90•Female

Primary endpoint

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Nih1R01AG029624-01

Org study IDIA0049

SecondaryIRB M1285

NCT IDNCT00065767

Timeline

Milestones

Study start2001-09 (month precision)

Study first posted2003-08-04estimated

Primary completion2005-03actual (month precision)

Study completion2005-03actual (month precision)

Last update posted2015-10-05estimated

Assets

Drug assets

raloxifene

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age55 Years

Maximum age90 Years

SexFemale

Healthy volunteersNot accepted

Inclusion criteria

•Postmenopausal women with Alzheimer's disease and without other dementias (diagnosed by study staff or from an outside clinic)

•Mini Mental Status Exam score greater than 15/30

Exclusion criteria

•History of deep vein thrombosis or blot clots

•Diabetes

•Active heart disease or stroke

•Liver problems including hepatitis

•Severe vision or hearing problems

•Tobacco use

Endpoints (0)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

No endpoints recorded for this trial.

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.